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Background: Relapsing polychondritis is a rare disease characterised by inflammation of cartilaginous and
proteoglycan rich structures. As there are only a few published single centre case series from all across the world,
we describe our experience with 26 patients at a tertiary centre in north India.
Methods: A retrospective study with all patients meeting Damiani and Levine’s modification of McAdam’s
diagnostic criteria. Clinical details, investigations, disease activity assessment [(Relapsing Polychondritis Disease
Activity Index (RPDAI)], treatment and outcomes were recorded.
Results: Ten men and sixteen women (median age 45 years) met the diagnostic criteria. Auricular chondritis (96%),
arthritis (54%), hearing impairment (42%), ocular (42%), dermal (26%), cardiovascular (11%) and laryngotracheal
involvement (11%) characterized the clinical presentations. The median RPDAI was 31 (range 9-66). Two patients
died during observation. Overall survival was 92.3% (median survival 13.5 years).
Conclusions: Apart from reduced laryngotracheal involvement, RP in India was clinically similar to recorded
patterns elsewhere.
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Relapsing Polychondritis (RP,Orpha 728) is usually a
recurring, autoimmune, inflammatory disorder predom-
inantly affecting cartilage and other proteoglycan rich
structures, with clinically significant ear, nose, articular
and tracheobronchial tree involvement. Significantly, the
eyes, heart and blood vessels may also be involved to a
variable degree. Although rare, it may be associated with
significant morbidity and mortality especially if associ-
ated with respiratory tract or cardiovascular involve-
ment. Its rarity however, is offset by typical clinical
features that enable a rapid diagnosis. Fortunately, it
usually responds rapidly and dramatically to immuno-
suppressive therapy. Case series from western nations
defined its clinical spectrum [1-3]. Smaller series from
south-east Asia and India have, however, depicted clin-
ical presentations at variance from those in Caucasian* Correspondence: amansharma74@yahoo.com
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unless otherwise stated.patients [4-6] (see Table 1). To document these differ-
ences, we present the largest single centre experience
from the Indian subcontinent.Methods
The study was performed at the Postgraduate Institute
of Medical Education and Research, a tertiary care
centre in northern India. The data of all patients
diagnosed with relapsing polychondritis registered with
the Rheumatology department from 1997 – 2014 was
collected and analysed. Twenty six patients who met the
diagnostic criteria defined by McAdam and modified by
Damiani and Levine were included in this analysis [1,8].
All patients underwent an extensive diagnostic evaluation
including a medical history, detailed physical examination
including an otolaryngological evaluation, assessment of
baseline haematological and metabolic parameters,
imaging evaluation of affected sites including transthoracic
echocardiography and, where indicated, angiography.
Laboratory evaluation included antinuclear antibody, anti
neutrophil cytoplasmic antibodies and rheumatoid factor.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,















Year of Publication 1976 1986 1998 2003 2009 2012 2014
No. of patients 159 112 66 12 7 30 26
Mean age at diagnosis 44 51 46 34 40 43 45
Female: Male 76:83 55:57 49:17 3:1 2.5:1 23:20 1.6:1
Auricular Chondritis (%) 89 85 95 83 57 88 96.1
Saddle Nose (%) NR 29 20 17 NR NR 11.5
Arthritis (%) 81 52 85 75 43 60 53.8
Hearing impairment (%) 46 30 42 17 NR 37 46.1
Ocular involvement (%) 65 51 57 67 43 57 42.3
Laryngeal/tracheal involvement (%) 56 48 67 50 43 37 11.5
Cardiovascular involvement (%) 9 6 8 8 14.3* NR 11.5
Skin involvement (%) 17 28 38 0 14.3* NR 26.9
Tracheostomy (%) 6 NR 5 42 NR NR 1*
Death (%) 6 NR 3 0 0 NR 8
*Single patient. Percentage may not be significant.
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using the Relapsing Polychondritis Disease Activity
Index (RPDAI) [9]. This scoring system takes into
account the disease manifesetations in a 28 day period.
The patients were followed up regularly in the out-
patients department as well as during any admission.
The study protocol was approved by the institute
ethics committee.Results
Twenty six patients (10 males, 16 females) aged 14-65
years (median 45 years) were included in this analysis.
The median duration of symptoms, prior to diagnosis,
was 2.5 months (7 days -5 years).Clinical features
Aural and nasal cartilage involvement dominated the
clinical presentation. Auricular chondritis was present in
twenty five patients (96.1%). Recurrent episodes were
noted in five (19.2%). A surgical procedure had been
performed in three patients (11.5%). Objective evidence
of hearing loss was noted in twelve patients (46.15%).
One patient had severe bilateral sensorineural hearing
loss. Nasal symptoms were reported by twenty one
patients (81%) The sequel of nasal bridge collapse was
reported in three of them (11.5%). Tracheobronchial
involvement was seen in three patients necessitating
tracheostomy in one of them.
Ocular involvement in the form of scleritis was seen in
eleven patients (42.3%) whereas two patients (7.7%) had
evidence of uveitis alone.Arthritis in fourteen patients (53.8%), skin rash in seven
patients (26.9%), oral and genital ulcers in four patients
(15.4%) were other frequently observed manifestations.
Cardiovascular involvement in the form of aortic
aneurysm or aortic annular dilatation was seen in three
patients (11.5%).
Coexistent autoimmune disorders were seen in four
patients (15.4%), three of whom met criteria for SLE.
One patient had nephrotic range proteinuria and was di-
agnosed to have minimal change disease on renal biopsy.
One patient had features of multicentricreticulohistiocyto-
sis. Three patients (11.5%) developed vasculitis- ANCA
associated vasculitis in one, cutaneous vasculitis in one
patient with SLE and retinal vasculitis in one patient. One
of these patients with cutaneous vasculitis had SLE.
Fourteen patients (53.8%) had a low haemoglobin below
120 g/L. Leucocyte counts, platelet count and metabolic
parameters were normal in all patients. The median
baseline RPDAI score was 31 (range 9 – 66).
Patients were followed up regularly in the clinic as well
as during any admission. The clinical course and thera-
peutic variables of three patients is included below to
depict our experience.
Case 1
A 47 year old female presented with a 6 month history
of fever, pain and swelling in both ears and hoarseness
accompanied by anorexia and a 10 Kg weight loss. She
also had pain and swelling of the small joints of her
hands, ankles and shoulders for the last 3 months with
early morning stiffness lasting over 2 hours. Physical
examination revealed acute and chronic inflammatory
changes in both ears with saddle nose deformity of the
Figure 1 Kaplan Meier survival curve of relapsing polychondritis
(n = 26).
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showed evidence of thyroid cartilage destruction. RPDAI
at the baseline was 38. She was managed with oral pred-
nisolone (1 mg/Kg/day), along with azathioprine (2 mg/
Kg/day) with prompt resolution of all symptoms. She
was weaned off steroids and continued on azathioprine
for 5 years. Azathioprine withdrawalresulted in relapse
with bilateral auricular chondritis necessitating reintro-
duction of both steroids and azathioprine. Presently, she
is only on azathioprine 150 mg/day, and is doing well
after a total follow up of eight years and five months.
Case 2
A 60 year old male was admitted with 1 month of fever,
redness of both eyes, pain in the nose and throat and
multiple small and large joint pains severe enough to
limit mobility. While no auricular involvement was
noted at admission, it developed within 24 hours. Exam-
ination revealed bilateral episcleritis, nasal and auricular
inflammation. Aortic regurgitation, clinically identified,
was confirmed by transthoracic echocardiography and
CT angiography. Aortic root diameter was 40 mm.
Radiological evidence of thyroid cartilage involvement
was present as was sensorineural hearing loss. RPDAI at
baseline was 54. The patient received three pulses of one
gram methyl prednisolone, along with a pulse of cyclo-
phosphamide. This was followed by oral prednisolone at
a dose of 1 mg/kg/day, which was gradually tapered over
ten months. He received six monthly pulses of intravenous
cyclophosphamide followed by azathioprine. As significant
transaminitis developed, azathioprinewas replaced by
mycophenolate mofetil. After four years on it, he devel-
oped severe arthritis, so it was replaced by methotrexate.
After 8 years, he is presently symptom free, on 15 mg/
week of methotrexate and there has been no further
increase in aortic root diameter.
Case 3
A 47 year old male presented with a history of recurrent
oral and genital ulcers with severe auricular and nasal
chondritis. He also had anterior uveitis and severe
bilateral large and small joint arthritis rendering him
wheelchair bound. A diagnosis of MAGIC syndrome
was made. RPDAI, at baseline, was 19. He was started
on oral prednisolone at a dose of 1 mg/kg/day resulting
in major symptomatic improvement. Azathioprine was
added as a steroid sparing agent at a dose of 150 mg per
day. At 12 months, he was able to resume work, steroids
were stopped after six months and azathioprine, continued.
Treatment
All patients were managed with immunosuppressive
therapy with corticosteroids being the first line in all
patients. Three patients required “pulse” cyclophosphamidefor exacerbations of disease and azathioprine, methotrexate
and mycophenolatemofetil were used in four (15.4%), three
(11.5%) and one patient (3.8%) respectively. The three
patients with concomitant SLE received hydroxychloro
quinesulphate in addition to steroids and other
immunosuppression.
At the time of writing this report, two patients died
during follow up. One patient succumbed to complica-
tions of pneumonia whereas the other patient had a
sudden cardiac death, possibly related to disease activity.
The overall survival was 92.3% and the median
survival was 13.5 years (Figure 1).
Discussion
Relapsing polychondritis is associated with multiple
clinical manifestations, all of which may not be identified
at the time of diagnosis. The key pathogenic mechanism
is the development of autoimmunity against cartilage
components including types II, IX and XI collagens as well
as other constituent proteins such as matrilin-1 [10]. At a
cellular level, it is likely that Th1 cells play a major role, as
evidenced by levels of interferon-γ, interleukin-12 and
interleukin-2 correlating with disease activity [11].
There is evidence of variability of disease presentation
in different ethnic populations. In a series of twelve
patients of south-east Asian and ethnic Chinese origin,
airway complications were more severe and cutaneous,
renal and neurological complications less frequent as
compared to Caucasian populations [4]. Two series have
been published from the Indian subcontinent. A study of
seven patients from southern India reported a reduced
frequency of ear and skin involvement as compared to
western data [6]. A series of ten patients from our
centre had shown less frequent airway related manifes-
tations [5].
Sharma et al. Orphanet Journal of Rare Diseases  (2014) 9:198 Page 4 of 6A genetic association has been described between RP
and HLA-DR4 in a study conducted in a series of 60
patients from Europe [12].
The median age of patients in this series was similar
to that reported in most other studies [12]. The youngest
patient in this series was 14 years old. Childhood RP has
been described and its clinical presentations are similar
to adult RP [13-15]. A family history of autoimmune
disease is often noted in these patients although they
infrequently have coexistent autoimmune diseases them-
selves [15].
The presence of auricular inflammation is characteris-
tic of RP and is an important diagnostic feature. The
inflammation typically spares the auricular lobe as it is
devoid of cartilage and this sign can aid in its differenti-
ation from other causes of auricular inflammation. This
manifestation was noted in nearly all patients at the time
of diagnosis (96.1%) in the present series and has been
reported in over 80% of patients in other studies as well
[12]. Multiple episodes of inflammation can result in
permanently deformed ears due to loss of cartilage com-
monly described as “cauliflower ears”. Involvement of
nasal cartilage can be seen in up to 56.5% of cases as
reported in the study by Zeuner et al. [12]. Our series
showed a higher incidence of 81% over the course of
disease. Saddle nose deformity was seen in 11.5%
patients. The incidence of arthritis was similar to previ-
ously published data.
Ocular involvement was noted in 42.3% patients in
this series. This number is higher than the incidence
reported in a series of southern Indian patients but simi-
lar to that reported in south-east Asian and CaucasianFigure 2 Scatter plot of patients showing RPDAI scores.populations. Severe inflammatory changes affecting
ocular tissues can lead to permanent damage and loss of
vision. Any part of the eye can be affected. Scleritis can
be particularly challenging to manage and may lead to
globe perforation [16]. Keratitis may also occur, leading
to corneal perforation [17].
Involvement of the tracheobronchial tree has been
reported to be present in approximately half of all
patients in western series [1,18]. The incidence of laryn-
geal, tracheal or bronchial involvement was 12% in our
patients contrasting with the higher rates reported in
other populations.
The coexistence of features of Behcet’s disease and RP
has been designated as MAGIC syndrome (Mouth And
Genital ulcers with Inflamed Cartilage) [19]. Three
patients in our series met the criteria for this diagnosis.
Renal disease has been described in RP. In a series
of 129 cases from the Mayo Clinic, renal disease was
identified in 23% of cases based on the presence of
hematuria, proteinuria or histopathological findings
[20]. The lesions commonly identified on biopsy
include mild mesangial proliferation followed by focal
and segmental glomerulonephritis with crescent
formation. Proteinuria in the nephrotic range was
identified in 14% cases in the series by Michet et al.
[2]. One patient had nephrotic range proteinuria in
our series and was found to have features of minimal
change disease on renal biopsy.
Parenchymal lung involvement was seen in one patient
in our series. This exceedingly rare manifestation has
not been described previously in literature and showed a
dramatic response to pulse methylprednisolone [21].
Sharma et al. Orphanet Journal of Rare Diseases  (2014) 9:198 Page 5 of 6An increased risk of myelodysplastic syndrome (MDS)
may exist in patients with RP [22,23]. In a single centre
series of 200 patients from France, MDS was seen in
11% [24]. Sweet’s syndrome has also been reported [25].
No patient, in this study, has developed a major haem-
atological complication to date.
Relapsing polychondritis often has a fluctuating
course and disease progression can be difficult to
predict. A scoring system has been devised in order to
provide an objective means of assessment of disease
severity [9]. Using this scoring system, our cohort of
patients demonstrated a median baseline RPDAI score
of 31 (range 9 – 66) (Figure 2).
The emerging role of nuclear medicine based imaging
has been a subject of interest and has a potential role in
the diagnosis and evaluation of disease activity in RP
due to its ability to identify subclinical lesions prior to
the onset of frank symptoms [26].
The mainstay of therapy revolves around control of
inflammation and suppression of autoimmunity. The
choice of therapy is dependent on the severity of symp-
toms and the extent of disease. Localised disease with
mild symptoms affecting the ear, nose or joints may be
treated with non steroidal anti-inflammatory drugs
(NSAIDS). For more severe symptoms, organ threatening
or multiple system disease corticosteroids such as oral
prednisolone (0.5 – 1.0 mg/kg/day) or “pulse” methyl-
prednisolone (1000 mg/day) may be appropriate. Dap-
sone alone or in conjunction with steroids may be
considered in milder forms of disease [8]. Other agents
such as cyclophosphamide, azathioprine, methotrexate,
cyclosporine, colchicine and chlorambucil may also be
considered as second line options in case of organ or
life threatening disease or as steroid sparing agents. In
our series, pulse methylprednisolone was used in a pa-
tient with severe cardiovascular complications (aortic
root dilatation) leading to excellent response [27].
Pulse cyclophosphamide was used in three patients
with severe and recalcitrant disease.
Emerging treatment options include the use of immu-
nomodulatory agents such as infliximab, etanercept, ada-
limumab and abatacept [28-31]. Tocilizumab, has shown
utility in patients with disease unresponsive to TNF an-
tagonists [32]. Allogeneic and autologous hematopoietic
stem cell transplantation remains a controversial subject,
but may be of potential utility in refractory cases [33].
The life expectancy of patients with RP may be
reduced due to its progressive nature, however due to
the advent of better therapeutic modalities and early
diagnosis, the survival at 8 years may be as high as
94% [3].
Our study is limited by the relatively small number of
patients and the referral bias inherent with a study
conducted at an tertiarycentre.Conclusions
Relapsing polychondritis is a progressive and potentially
lethal autoimmune disease affecting multiple organs and
tissues. Early recognition of the signs of this disease and
prompt initiation of anti-inflammatory and immunosup-
pressive therapy can ameliorate symptoms and prevent
end organ complications, particularly those affecting the
respiratory tract and the heart.
Emerging diagnostic modalities such as FDG-PET
scanning and newer immunosuppression strategies
provide hope for improved outcomes. The RPDAI may
provide an accurate and objective estimation of dis-
ease activity.
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